Ozempic, Wegovy, Mounjaro: The Real Numbers Behind the GLP-1 Boom

Q2

Wegovy revenue grew 86% in 2024 — yet Novo Nordisk's share of new-to-brand GLP-1 prescriptions fell to 38.8% by Q3 2025. How do you read a market where total revenues rise but new patient share falls?

Ans.

This is a market in transition, not decline.  Rising revenue alongside falling new-patient share is a classic late-growth signal: the installed base is large enough to drive revenue even as competitive pressure on new starts intensifies. Eli Lilly's Zepbound and Mounjaro are winning a disproportionate share of first-time prescriptions, particularly in obesity, while Novo Nordisk retains dominance in the longer-standing diabetes patient base.

The strategic risk for Novo Nordisk is not today's revenue — it is the 2-3 year pipeline of patients who are starting on tirzepatide and may never switch. The strategic opportunity is that their oral semaglutide pipeline and next-generation combination molecules (CagriSema) are designed to recapture that new-patient share. Watch new-to-brand prescription share as the leading indicator — revenue will follow it with an 18-24 month lag.

Q3

The FDA granted three major new indications in under 18 months — cardiovascular, sleep apnea, and liver disease (MASH). At what point does this class stop being a 'weight loss drug' and become metabolic infrastructure?

Ans.

It already has, clinically.  The reclassification from weight loss drug to metabolic platform happened in the physician and regulatory community with the SELECT cardiovascular trial results in 2024. What lags behind is payer and insurance coverage policy — which is still largely coded to obesity as the primary indication.

The commercial inflection point will come when GLP-1 drugs are reimbursed primarily for cardiovascular risk prevention — at which point the addressable population expands from the obese to the broadly cardiometabolic at-risk population, which is a multiple of the current base. The MASH and sleep apnea approvals are early evidence of this reclassification hardening. Analysts should track CMS coverage policy changes and employer formulary decisions as the leading signals.

Q4

Clinical trial data showed a 94% reduction in Type 2 diabetes risk in pre-diabetic patients on tirzepatide. If GLP-1 obesity drugs prevent diabetes at scale, what happens to the diabetes drug revenue that the same companies depend on?

Ans.

The cannibalisation risk is real but structurally manageable — for now.  Both Novo Nordisk and Eli Lilly sell GLP-1 drugs for both obesity and diabetes. If obesity-indication GLP-1 drugs prevent Type 2 diabetes in pre-diabetic patients, fewer patients enter the diabetes treatment pool. This reduces the long-term addressable market for diabetes drugs — including their own older GLP-1 and insulin portfolios.

However, the companies are partially hedged: their obesity drugs carry higher price points than older diabetes drugs, and the prevented-diabetes patient still takes a GLP-1 for obesity prevention — so revenue shifts upward in margin terms even if volume in the diabetes segment softens. The real exposure is to legacy insulin revenue, which carries lower margins and faces both GLP-1 substitution and biosimilar pressure simultaneously. Novo Nordisk's insulin business is the segment most vulnerable to this dynamic.

Q5

International Operations represent only 5.2% of total GLP-1 diabetes prescriptions while North America generates the majority of revenue. Which geography is most likely to be the next breakout market?

Ans.

The penetration gap is a reimbursement and infrastructure problem, not a demand problem.  Patient demand for GLP-1 drugs is high across most high-income markets. What varies is whether payer systems will fund it at scale. The markets closest to enabling volume adoption are Germany (where the G-BA has begun benefit assessments for semaglutide in obesity), Japan (where obesity drug reimbursement is expanding under national health policy reform), and the UAE/Saudi Arabia (where high obesity prevalence, government health mandates, and cash-pay capacity converge).

China is the highest-volume opportunity but the most uncertain — domestic GLP-1 competitors (Hengrui, Innovent) are already in the market with lower-priced candidates, meaning the Western companies face a pricing-down dynamic rather than a clean market entry. The most likely near-term revenue breakout outside the US is Germany and the Gulf, not China.